Business Wire

Airlines Were on Time in 2020, but Passenger Flights Operated Halved Compared to 2019, Reveals Cirium

Share

Over 180 of the major global airlines were on time in 2020, according to a new report by Cirium, the global aviation data company. The Cirium Airline Insights Review 2020 reveals that only 30 major airlines achieved this standard pre-pandemic. But over 60%—or 180 of 300 airlines globally—achieved a 90% or higher on-time arrival percentage since February 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210104005632/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cirium’s new report The Cirium Airline Insights Review 2020 reveals the world’s top 10 busiest airports of 2020. (Graphic: Business Wire)

On-time performance of the top 300 global airlines significantly improved as COVID-19 reduced the number of flights in the air. In 2020, airlines only flew half of the flights flown the previous year.

“The pandemic caused a significant reduction in flight volume with airlines operating 49% fewer flights in 2020. The factors that normally cause flight delays didn’t exist, such as congestion at the airport. Overall global passenger traffic was down in 2020 by 67% from the previous year,” said Jeremy Bowen, CEO of Cirium.

Cirium’s top 10 league table for flights operated by country shows that the majority of flights were operated in the US, despite a 42% year-over-year drop in the market. China maintained its position, with only 24% of that market’s flights down versus 2019.

Japan overtook India, moving up to 3rd place as India’s flights were down 50% versus 2019. The UK was hit heavily with 67% of flights down compared to last year, moving it to 8th place from 5th. Russia moved from 10th place in 2019 to 5th in 2020 and Indonesia moved into the top 10.

Top 10 countries by passenger flights flown 2020

Rank

Country

Total flights flown 2020

Rank in 2019

% YoY diff

1

United States

5.1M

#1

-42%

2

China

3.4M

#2

-24%

3

Japan

638K

#4

-43%

4

India

592K

#3

-50%

5

Russia

486K

#10

-34%

6

Brazil

382K

#9

-53%

7

Spain

352K

#7

-61%

8

United Kingdom

340K

#5

-67%

9

Indonesia

333K

#12

-53%

10

Mexico

332K

#15

-44%

 

Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021

Asia-Pacific carriers recovered much quicker in 2020 than their global peers and rose in the rankings in flights operated. Out of the top 10 global airlines, China Southern Airlines’ passenger flights only dropped 28% versus 2019. United Airlines was the most impacted of the top 10, with a 54% drop in flights flown versus 2019.

No European carriers feature in the 2020 list. Ryanair moved to 13th place (from 6th) as the airline’s flights flown were down 72% versus the year before. Lufthansa was 11th in 2019 but missed out on the 2020 top 10, finishing at 29th place as flights flown dropped by 69% in 2020.

Top 10 airlines by passenger flights flown 2020

Rank

Airline code

Airline

Total flights flown 2020

Rank in 2019

% YoY diff

1

WN

Southwest Airlines

896K

#1

-34%

2

AA

American Airlines

622K

#3

-44%

3

DL

Delta Air Lines

619K

#2

-46%

4

OO

SkyWest Airlines

597K

#4

-30%

5

CZ

China Southern Airlines

521K

#7

-28%

6

UA

United Airlines

372K

#5

-54%

7

MU

China Eastern Airlines

321K

#9

-33%

8

CA

Air China

312K

#10

-30%

9

6E

IndiGo

281K

#8

-45%

10

YX

Republic Airways

217K

#15

-37%

Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021

“Domestic travel has recovered faster and airlines with a dominant domestic market come back quicker,” Bowen said. “That is especially the case in Asia-Pacific where recovery is more positive. The US and Europe have experienced setbacks with government-enforced restrictions and additional waves of COVID-19 affecting travel.”

Travel restrictions and the shift to more leisure travel versus business travel changed the top 10 league table for flights flown by airport extensively.

Chicago O’Hare is usually the busiest airport globally for passenger flights, however the pandemic caused a 46% reduction in flights for the airport in 2020. Three Chinese airports—Guangzhou Baiyun, Chengdu Shuangliu, and Shenzhen Bao’an—moved into the global top 10 busiest airports by arriving passenger flights.

Top 10 airports by passenger flights flown 2020

Rank

Airport code

Airport

Total flights flown 2020

Rank in 2019

% YoY diff

1

ATL

Atlanta US

260K

#2

-40%

2

DFW

Dallas US

235K

#3

-30%

3

ORD

Chicago US

234K

#1

-46%

4

DEN

Denver US

202K

#5

-32%

5

CLT

Charlotte US

182K

#7

-32%

6

CAN

Guangzhou CN

165K

#13

-28%

7

LAX

Los Angeles US

156K

#4

-50%

8

CTU

Chengdu CN

148K

#37

-16%

9

SZX

Shenzhen CN

139K

#42

-16%

10

SEA

Seattle US

137K

#18

-36%

Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021

In 2019, London Heathrow was the 9th busiest airport for flights flown. In 2020, it ranked 31st and flights operating there were down 61% versus 2019. Amsterdam Airport Schiphol was the busiest airport in Europe. Flight operations there dropped 57% in 2020 and as a result the airport sits at 27th globally.

The Cirium Airline Insights Review 2020 provides additional insights on 2020 air travel industry and includes The On-Time Performance Review 2020 by Cirium.

To read the full Cirium Airline Insights Review 2020 – click here.

Ends

Note to editors:

Data for the passenger flights flown is based on set criteria, which includes passenger flights only (including combination flights – passenger and cargo) that are scheduled and aircraft market classes of narrowbody, widebody, and regional jets. It excludes other types, such as cargo and business jet flights, as well as unscheduled flights.

For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter.

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries, please contact,

In the UK: Paul Charles / Michael Johnson / Balint Brunner at The PC Agency via cirium@pc.agency or +44 207 768 0001

In the Americas: Mike Arnot, at Juliett Alpha via cirium@juliettalpha.com

In Asia-Pacific: Tracy Cheung, at Cirium via tracy.cheung@cirium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye